Identification of culprit drugs when managing cutaneous drug eruptions is essential. Causality assessment methods (CAMs) have been proposed, including lab-based techniques. However, no consensus guidelines exist.
Objectives
To identify and map the functionality and feasibility of lab-based CAMs.
Methods
A scoping review was conducted to identify culprit drug identification methods. Publications on lab-based methods were analyzed. Medline, Embase, and Cochrane Central Register of Controlled Trials databases were searched.
Results
Twenty-five publications met inclusion criteria. Nine lab-based CAMs were studied, including lymphocyte transformation test, cytokine measurement (ELISpot, ELISA, beads array assay), modified IFN-ɣ ELISpot, CellScan, histamine release, granzyme B-ELISpot, intracellular granulysin, lymphocyte toxicity assay, and HLA allele genotyping. Diagnostic accuracy was reported for 8/9 methods. Clinical assessment and operational algorithms were commonly used as validation benchmarks. Lab-based methods were assessed at different phases of a drug eruption including in the acute (18.1%), recovery (27.3%), acute and recovery (27.3%), or an unspecified phase (27.3%). Lymphocyte transformation test (specificity 30% to 100%, sensitivity 27% to 73%) and cytokine measurement (specificity 76% to 100%, sensitivity 20% to 84%) were the most common methods studied.
Conclusions
Lab-based CAMs can be low-risk, effective, and complementary of clinical methods. High-quality studies are needed to adequately develop and validate these tools for clinical practice.
MockenhauptM. Epidemiology of cutaneous adverse drug reactions. Allergol Select. 2017;1(1):96-108.doi:10.5414/ALX01508E30402608
2.
DuongTA.Valeyrie-AllanoreL.WolkensteinP.ChosidowO. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996-2011.doi:10.1016/S0140-6736(16)30378-628476287
3.
DemolyP.AdkinsonNF.BrockowKet al. International consensus on drug allergy. Allergy. 2014;69(4):420-437.doi:10.1111/all.1235024697291
4.
ZhaoJ.HuL.ZhangL.ZhouM.GaoL.ChengL. Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference. Drug Saf. 2017;10(10):194-198.
5.
AgbabiakaTB.SavovićJ.ErnstE. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf. 2008;31(1):21-37.doi:10.2165/00002018-200831010-0000318095744
6.
MacedoAF.MarquesFB.RibeiroCF.TeixeiraF. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiol Drug Saf. 2005;14(12):885-890.doi:10.1002/pds.113816059869
7.
MacedoAF.MarquesFB.RibeiroCF. Can decisional algorithms replace global introspection in the individual causality assessment of spontaneously reported ADRs?Drug Saf. 2006;29(8):697-702.doi:10.2165/00002018-200629080-0000616872243
8.
KotruljaL.Milavec-PureticV.PasicA. Diagnostic methods in the determination of drug allergy. Acta Dermatovenerologica Croat. 1997;5(3):111-116.
9.
PorebskiG.Pecaric-PetkovicT.Groux-KellerM.BosakM.KawabataTT.PichlerWJ. In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test. Clin Exp Allergy. 2013;43(9):1027-1037.doi:10.1111/cea.1214523957338
10.
KlaewsongkramJ.SukasemC.ThantiworasitPet al. Analysis of HLA-B allelic variation and IFN-γ ELISpot responses in patients with severe cutaneous adverse reactions associated with drugs. J Allergy Clin Immunol Pract. 2019;7(1):219-227.doi:10.1016/j.jaip.2018.05.00429800753
11.
TriccoAC.LillieE.ZarinWet al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-473.doi:10.7326/M18-085030178033
12.
ThéophileH.ArimoneY.Miremont-SalaméGet al. Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre. Drug Saf. 2010;33(11):1045-1054.doi:10.2165/11537780-000000000-0000020925441
13.
Bastuji-GarinS.RzanyB.SternRS.ShearNH.NaldiL.RoujeauJC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96.doi:10.1001/archderm.1993.016802201040238420497
14.
Auquier-DunantA.MockenhauptM.NaldiLet al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8):1019-1024.doi:10.1001/archderm.138.8.101912164739
15.
AssierH.Bastuji-GarinS.RevuzJ.RoujeauJC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131(5):539-543.doi:10.1001/archderm.1995.016901700410057741539
16.
InnovationVH. Covidence systematic review software, Veritas Health Innovation; 2020. www.covidence.org
17.
KatoK.KawaseA.AzukizawaHet al. Novel interferon-γ enzyme-linked immunoSpot assay using activated cells for identifying hypersensitivity-inducing drug culprits. J Dermatol Sci. 2017;86(3):222-229.doi:10.1016/j.jdermsci.2017.03.00728330775
18.
BorchJE.AndersenKE.Bindslev-JensenC. The prevalence of acute cutaneous drug reactions in a Scandinavian university hospital. Acta Derm Venereol. 2006;86(6):518-522.doi:10.2340/00015555-014317106599
19.
KanoY.HiraharaK.MitsuyamaY.TakahashiR.ShioharaT. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439-1444.doi:10.1111/j.1398-9995.2007.01553.x17983378
20.
KaramiZ.MesdaghiM.KarimzadehPet al. Evaluation of lymphocyte transformation test results in patients with delayed hypersensitivity reactions following the use of anticonvulsant drugs. Int Arch Allergy Immunol. 2016;170(3):158-162.doi:10.1159/00044828427560351
21.
CabañasR.CalderónO.RamírezEet al. Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. Clin Exp Allergy. 2018;48(3):325-333.doi:10.1111/cea.1307629265576
22.
GoldbergI.HansonM.ChodickG.ShiraziI.BrennerS.MaggiE. In vitro release of interferon-gamma from peripheral blood lymphocytes in cutaneous adverse drug reactions. Clin Dev Immunol. 2012;2012:1-7.doi:10.1155/2012/68753222719779
23.
NaranjoCA.KwokMC.LanctôtKL.ZhaoHP.SpielbergSP.ShearNH. Enhanced differential diagnosis of anticonvulsant hypersensitivity reactions by an integrated Bayesian and biochemical approach. Clin Pharmacol Ther. 1994;56(5):564-575.doi:10.1038/clpt.1994.1787955821
24.
SalamehF.KravitzMS.BarzilaiAet al. Clinical application of static fluorescence-based cytometry, Cellscan, in cutaneous adverse drug reaction. J Dermatol. 2011;38(5):447-455.doi:10.1111/j.1346-8138.2010.01000.x21352273
25.
GoldbergI.GilburdB.KravitzMSet al. A novel system to diagnose cutaneous adverse drug reactions employing the cellscan--comparison with histamine releasing test and Inf-gamma Releasing Test. Clin Dev Immunol. 2005;12(1):85-90.doi:10.1080/1044667041000172223015712603
BergmannMM.CaubetJ-C. Role of in vivo and in vitro tests in the diagnosis of severe cutaneous adverse reactions (scar) to drug. Curr Pharm Des. 2019;25(36):3872-3880.doi:10.2174/138161282566619110710412631696801
28.
SharmaVK.SethuramanG. Adverse cutaneous reactions to drugs: an overview. J Postgrad Med. 1996;42(1):15-22.9715291
29.
ArizaA.TorresMJ.Moreno-AguilarC.Fernández-SantamaríaR.FernándezTD. Early biomarkers for severe drug hypersensitivity reactions. Curr Pharm Des. 2019;25(36):3829-3839.doi:10.2174/138161282566619110710544031696802
30.
AbererW. Drug hypersensitivities: the need for standardization. Eur Ann Allergy Clin Immunol. 2005;37(6):219-222.16156400
31.
BurbachGJ.ZuberbierT. Diagnosis of drug-induced skin reactions: a future role for computer-aided systems?Curr Opin Allergy Clin Immunol. 2011;11(5):451-456.doi:10.1097/ACI.0b013e32834a974c21785347
32.
BarbaudAGonçaloMBruynzeelDBircherAEuropean Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001;45(6):321-328.doi:10.1034/j.1600-0536.2001.450601.x11846746
33.
PaulmannM.MockenhauptM. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges. 2015;13(7):625-643.doi:10.1111/ddg.1274726110722
34.
Ingen-Housz-OroS.DuongT-A.BensaidBet al. Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de diagnostic et de soins). Orphanet J Rare Dis. 2018;13(1):56.doi:10.1186/s13023-018-0793-729636107
35.
MereniukA.JaqueA.JeschkeMG.ShearNH. Toxic epidermal necrolysis spectrum management at Sunnybrook health sciences centre: our multidisciplinary approach after review of the current evidence. J Cutan Med Surg. 2018;22(2):213-219.doi:10.1177/120347541774614829202605
36.
Dodiuk-GadRP.ChungW-H.Valeyrie-AllanoreL.ShearNH. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16(6):475-493.doi:10.1007/s40257-015-0158-026481651
37.
Ardern-JonesMR.MockenhauptM. Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Curr Opin Allergy Clin Immunol. 2019;19(4):283-293.doi:10.1097/ACI.000000000000054631247634
38.
CabañasR.RamírezE.SendagortaEet al. Spanish guidelines for diagnosis, management, treatment, and prevention of dress syndrome. J Investig Allergol Clin Immunol. 2020;30(4):229-253.doi:10.18176/jiaci.048031932268
39.
LowYS.CasterO.BergvallTet al. Cheminformatics-aided pharmacovigilance: application to Stevens-Johnson syndrome. J Am Med Inform Assoc. 2016;23(5):968-978.doi:10.1093/jamia/ocv12726499102
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
